Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Artara Therapeutics Inc (TARA)

Artara Therapeutics Inc (TARA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Protara Therapeutics Closes $100 Million Public Offering to Fund Clinical Development

Protara Therapeutics closed a $100 million public offering to fund clinical development of its therapies.Quiver AI SummaryProtara Therapeutics, Inc. announced the completion of its public offering of 13,690,000...

TARA : 5.15 (-4.45%)
Protara Announces Closing of $100 Million Public Offering

TARA : 5.15 (-4.45%)
Protara Therapeutics Announces Commencement of Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Protara Therapeutics announced a public offering of common stock to fund clinical development programs.Quiver AI SummaryProtara Therapeutics, Inc. has announced the initiation of an underwritten public...

TARA : 5.15 (-4.45%)
Protara Announces Pricing of $100 Million Public Offering

TARA : 5.15 (-4.45%)
Protara Announces Proposed Public Offering

TARA : 5.15 (-4.45%)
Protara Therapeutics Reports Positive Phase 2 Results for TARA-002 in Non-Muscle Invasive Bladder Cancer

TARA-002 shows promising response rates in NMIBC patients, with favorable safety and tolerability in a Phase 2 trial.Quiver AI SummaryProtara Therapeutics, Inc. announced promising results from its Phase...

TARA : 5.15 (-4.45%)
Protara Therapeutics Stock Doubles On Promising Bladder Cancer Trial Data: Retail Buzz Spikes

The data will be presented during a poster session at the 25th Annual Meeting of the Society of Urologic Oncology in Dallas, Texas, the company said.

TARA : 5.15 (-4.45%)
Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

TARA : 5.15 (-4.45%)
Protara Therapeutics Announces Conference Call to Discuss Interim Analysis of TARA-002 in Phase 2 NMIBC Trial

Protara Therapeutics will present interim Phase 2 trial data for TARA-002 in NMIBC on December 5, 2024.Quiver AI SummaryProtara Therapeutics, Inc. announced that it will host a conference call and live...

TARA : 5.15 (-4.45%)
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024

TARA : 5.15 (-4.45%)

Barchart Exclusives

3 Pharma Stocks to Buy as California Sounds the Alarm on Bird Flu Cases
The bird flu crisis is creating investment opportunities in the pharmaceutical sector, with Sanofi, GSK, and CSL Limited emerging as top picks. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar